AMRITX

We have developed a drug design algorithm, integrated within our therapeutic discovery platform, CANDO (Computational Analysis of Novel Drug Opportunities), which leverages multiscale data to rapidly generate unique, effective, and safe drugs de novo. The novelty of this approach lies in the use of full organismal proteomes to tailor molecules for specific therapeutic uses, while considering toxicity and other pharmacological properties. This approach is in direct contrast to traditional drug discovery pipelines in which a single protein target is used in a large-scale screen of compounds/drugs for a single disease/indication.

Also known as: AmritX Inc